|Articles|May 15, 2002
Growth is forecast: Alcon IPO raises $2.5 billion in partial Nestle divestiture
Fort Worth, TX-Alcon Inc.'s successful initial public offering (IPO) not only confirms the stability of the company, but positions it well for future growth and investment, according to company officials and analysts.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
2
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
5














































.png)


